Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Liabilities and Shareholders Equity (2021 - 2025)

Bioregenx (BRGX) has 5 years of Liabilities and Shareholders Equity data on record, last reported at $1.2 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 93.27% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $3.3 million, down 93.95%, while the annual FY2024 figure was $508535.0, 41.26% down from the prior year.
  • Liabilities and Shareholders Equity reached $1.2 million in Q3 2025 per BRGX's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $18.6 million in Q1 2024 and bottomed at $33981.0 in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $4.5 million, with a median of $508535.0 recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 50991.39% in 2024, then crashed 97.41% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $127762.0 in 2021, then crashed by 53.7% to $59149.0 in 2022, then skyrocketed by 1363.68% to $865750.0 in 2023, then tumbled by 41.26% to $508535.0 in 2024, then surged by 129.63% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.2 million in Q3 2025, $1.2 million in Q2 2025, and $482623.0 in Q1 2025.